Postnatal corticosteroid exposure in very preterm infants: A French cohort study

Silvia Iacobelli1,2, Käliani Allamèle-Moutama2, Simon Lorrain2

  • 1Néonatologie, Réanimation Néonatale et Pédiatrique, CHU Saint Pierre, Saint Pierre, France.

Insights

Around 26% of very preterm infants received postnatal corticosteroids (PC) in French NICUs, often early in life for respiratory issues or hypotension. Significant center-to-center variability in PC use was observed.

Area of Science:

  • Neonatology
  • Pediatric Pharmacology
  • Clinical Pharmacy

Background:

  • Postnatal corticosteroids (PC) are frequently used in very preterm infants.
  • Significant variability exists in PC prescribing practices across different centers and countries.
  • Limited data are available on specific therapeutic indications and prescription patterns of PC.

Purpose of the Study:

  • To describe PC exposure in a large French cohort of preterm infants (<32 weeks gestation).
  • To analyze therapeutic indications, timing of first exposure, route, duration, and cumulative dose of PC.
  • To investigate variations in PC exposure rates among participating tertiary care neonatal intensive care units (NICUs).

Main Methods:

  • Prospective observational cohort study conducted from January 2017 to December 2021.
  • Data collected from 41 French tertiary-care NICUs utilizing a standardized computerized order-entry system.
  • Analysis included 13,913 very preterm infants.

Main Results:

  • Overall, 26.1% of infants were exposed to PC (21.8% systemic, 10.1% inhaled).
  • Common indications included bronchopulmonary dysplasia and arterial hypotension; hydrocortisone was most prescribed.
  • Exposure rates varied widely (5%-56%) across centers and increased significantly over the study period.

Conclusions:

  • Approximately one in five very preterm infants in this French cohort received PC during NICU stay.
  • PC exposure frequently occurred within the first week of life, with notable inter-center variations.
  • Pharmacoepidemiological studies are crucial for understanding and optimizing corticosteroid use in preterm infants.

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
324
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.6K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
164
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
257